No Data
Guofa Co., Ltd.: Summary of the 2024 annual report of China Fa Co., Ltd.
Guofa Co., Ltd.: Full text of Guofa Co., Ltd.\'s 2024 annual report
Full text of the 2024 Annual Report of China Development Co., Ltd.
Summary of the 2024 annual report of China Development Corporation
Beihai Gofar Chuanshan Biological (600538.SH): A net loss of 93.8502 million yuan is expected in 2024.
Gelonghui reported on April 21 that Beihai Gofar Chuanshan Biological (600538.SH) announced its annual report for 2024. In 2024, the company achieved revenue of 0.34 billion yuan, a year-on-year decrease of 7.77%, with a net income attributable to the parent company's owners of -93.8502 million yuan. (1) The company's wholly-owned subsidiary Goldman Sachs Biological: due to intensified market competition, management expenses increased by 4.29 million yuan, a year-on-year increase of 25%; at the same time, affected by the tight funding of police unit clients, accounts receivable increased, payment periods were extended, and credit impairment losses were accrued at 6.54 million yuan, an increase of 75%. This led to its net income falling.
Beihai Gofar Chuanshan Biological Co., Ltd. (SHSE:600538) Investors Are Less Pessimistic Than Expected
There's Reason For Concern Over Beihai Gofar Chuanshan Biological Co., Ltd.'s (SHSE:600538) Massive 26% Price Jump